Zanamivir, a new targeted therapy in the treatment of influenza. A patient perspective assessed by questionnaire

Clinical Drug Investigation

Volumn 19, Issue 2, 2000, Pages 111-121

  Silagy, C ^a   Watts, R ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b Investigator Clinic   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ZANAMIVIR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; DRUG EFFICACY; FEMALE; FEVER; GENERAL PRACTITIONER; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 0034007382     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019020-00004     Document Type: Article

References (16)

1. Morbidity and Mortality Weekly Report 1999; 48 (29): 623
2. Osterhaus A. H5N1: the lessons learned. In: Zambon MC, editor. Advances in influenza. International Medical Forum 104. Oxford: Blackwell Science Ltd, 1999
3. Aoki FY. Amantidine and rimantidine. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science Ltd, 1998: 457-76
4. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275 (4): 295-9
5. Aoki FY, Hayden FG. The pharmacokinetics of Zanamivir: a new inhaled antiviral for influenza. Clin Pharmacokinet 1999; 36 Suppl. 1: 1-58
6. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874-80
7. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomised controlled trial. JAMA 1999; 282 (1): 31-5
8. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352 (9144): 1877-81
9. Monto AS, Webster A, Keene O. Randomised, placebo controlled studies of inhaled zanamivir in the treatment of influenza A and B - pooled efficacy analysis. J Antimicrob Chemother 1999; 44 Topic B: 23-9
10. von Itzstein I, Wu W-Y, Kok G, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23
11. Zanamivir Prescribing Information Glaxo Wellcome, Boronia Australia 1999
12. National Centre for Disease Control, Commonwealth Department of Health and Aged Care and Communicable Diseases Network of Australia and New Zealand. Communicable Diseases Intelligence, Australia (internet site: htp://www.health. gov.au/pubhlth/cdi)
13. Glaxo Wellcome. Data on file
14. Nicholson KG. Epidemiology. In: Nicholson KG editor. Managing influenza in primary care. Oxford: Blackwell Science Ltd, 1999: 26
15. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science Ltd, 1998: 358-72
16. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science Ltd, 1998: 219-64